News

 In a new preclinical study conducted by MHRP, an HIV vaccine formulated with a novel adjuvant called AFLA developed at the Walter Reed Army Institute of Research elicited stronger immune responses than a vaccine with a more commonly used alum adjuvant. Findings from the study were published in PLOS Pathogens.

Researchers immunized rhesus macaques with a prime-boost HIV-1 vaccine...

We are pleased to announce that LTC(P) Julie Ake has been selected as the next Director of the U.S. Military HIV Research Program (MHRP), effective June 30. LTC(P) Ake has been with MHRP at the Walter Reed Army Institute of Research since 2010 and has served as the Principal Deputy Director for MHRP the last three years. Most recently, she has also been serving as WRAIR’s Deputy Principal for...

A new MHRP study shows the eclipse phase between HIV infection and earliest diagnosis via RNA testing lasted about a week, based on molecular dating and viral load growth rates obtained from one of its acute infection cohorts. The results were published this week in PLOS Pathogens.

“Individuals living with HIV rarely know when they became infected, but precise infection timing would...

MHRP is counting down the top five program highlights of the year in the areas of HIV vaccine development, cure research and global health promotion. Check back each day as we count down to number one:

MHRP’s partner sites in Uganda, Kenya and Tanzania have enrolled more than 65,000 young women in PEPFAR’s DREAMS public-partnership initiatives. This program aims to keep them...